CoChat
Sign Up
Cited by 40

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Apolipoprotein D Upregulation in Alzheimer’s Disease but Not Frontotemporal Dementia

Bhatia, Surabhi, Kim, Woojin Scott, Shepherd, Claire E., Halliday, Glenda M.·2019·Journal of Molecular Neuroscience
DOI 10.1007/s12031-018-1217-9PMC PMC6344390
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12031-018-1217-9

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Relative expression of ApoD in TBS-soluble fraction in a the superior frontal cortex and b inferior temporal cortex. Data represents mean ± SD. Significance is at *p < 0.05
Fig. 1 Relative expression of ApoD in TBS-soluble fraction in a the superior frontal cortex and b inferior temporal cortex. Data represents mean ± SD. Significance is at *p < 0.05CC BY · PubMed Central
Fig. 2 Relative expression of TARDBP in a U87- and apoD-overexpressing cell line, b in U87 cells, and c U87 apoD cells under control vs treated (300 mm H2O2 for 24 h) conditions. Data represents mean ± SD. of n = 3 for 3 repeats
Fig. 2 Relative expression of TARDBP in a U87- and apoD-overexpressing cell line, b in U87 cells, and c U87 apoD cells under control vs treated (300 mm H2O2 for 24 h) conditions. Data represents mean ± SD. of n = 3 for 3 repeatsCC BY · PubMed Central
Fig. 3 Relative expression of APP in (a) U87- and apoD-overexpressing cell line, b in U87 cells, and c U87 apoD cells under control vs treated (300 mm H2O2 for 24 h) conditions. Data represents mean ± SD of n = 3 for 3 repeats. Significance is at *p < 0.05
Fig. 3 Relative expression of APP in (a) U87- and apoD-overexpressing cell line, b in U87 cells, and c U87 apoD cells under control vs treated (300 mm H2O2 for 24 h) conditions. Data represents mean ± SD of n = 3 for 3 repeats. Significance is at *p < 0.05CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Research works printed but not linked: 50

  1. Arai T, Ikeda K, Akiyama H, Shikamoto Y, Tsuchiya K, Yagishita S, Beach T, Rogers J, Schwab C, McGeer P (2001) Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 101:167–173 · DOI
  2. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602–611. https://doi.org/10.1016/j.bbrc.2006.10.093 · DOI · Paper page
  3. Bajo-Grañeras R, Ganfornina MD, Martín-Tejedor E, Sanchez D (2011a) Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systems. Glia 59:1551–1566. https://doi.org/10.1002/glia.21200 · DOI
  4. Bajo-Grañeras R, Sanchez D, Gutierrez G, González C, Do Carmo S, Rassart E, Ganfornina MD (2011b) Apolipoprotein D alters the early transcriptional response to oxidative stress in the adult cerebellum. J Neurochem 117:949–960. https://doi.org/10.1111/j.1471-4159.2011.07266.x · DOI
  5. Belloir B, Kovari E, Surini-Demiri M, Savioz A (2001) Altered apolipoprotein D expression in the brain of patients with Alzheimer disease. J Neurosci Res 64:61–69. https://doi.org/10.1002/jnr.1054 · DOI
  6. Bhatia S, Jenner AM, Li H, Ruberu K, Spiro AS, Shepherd CE, Kril JJ, Kain N, Don A, Garner B (2013) Increased apolipoprotein D dimer formation in Alzheimer’s disease hippocampus is associated with lipid conjugated diene levels. J Alzheimers Dis 35:475–486. https://doi.org/10.3233/jad-122278 · DOI
  7. Bloom GS (2014) Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol 71:505–508. https://doi.org/10.1001/jamaneurol.2013.5847 · DOI
  8. Broe M, Kril J, Halliday GM (2004) Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain 127:2214–2220. https://doi.org/10.1093/brain/awh250 · DOI · Paper page
  9. Cacabelos D, Ayala V, Granado-Serrano AB, Jové M, Torres P, Boada J, Cabré R, Ramírez-Núñez O, Gonzalo H, Soler-Cantero A, Serrano JCE, Bellmunt MJ, Romero MP, Motilva MJ, Nonaka T, Hasegawa M, Ferrer I, Pamplona R, Portero-Otín M (2016) Interplay between TDP-43 and docosahexaenoic acid-related processes in amyotrophic lateral sclerosis. Neurobiol Dis 88:148–160. https://doi.org/10.1016/j.nbd.2016.01.007 · DOI
  10. Cohen TJ, Hwang AW, Unger T, Trojanowski JQ, Lee VM (2012) Redox signalling directly regulates TDP-43 via cysteine oxidation and disulphide cross-linking. EMBO J 31:1241–1252. https://doi.org/10.1038/emboj.2011.471 · DOI
  11. Dassati S, Waldner A, Schweigreiter R (2014) Apolipoprotein D takes center stage in the stress response of the aging and degenerative brain. Neurobiol Aging 35:1632–1642. https://doi.org/10.1016/j.neurobiolaging.2014.01.148 · DOI · Paper page
  12. de Magalhaes JP, Curado J, Church GM (2009) Meta-analysis of age-related gene expression profiles identifies common signatures of aging. Bioinformatics 25:875–881. https://doi.org/10.1093/bioinformatics/btp073 · DOI · Paper page
  13. Desai PP, Ikonomovic MD, Abrahamson EE, Hamilton RL, Isanski BA, Hope CE, Klunk WE, DeKosky ST, Kamboh MI (2005) Apolipoprotein D is a component of compact but not diffuse amyloid-beta plaques in Alzheimer’s disease temporal cortex. Neurobiol Dis 20:574–582. https://doi.org/10.1016/j.nbd.2005.04.012 · DOI
  14. Dickson DW, Kouri N, Murray ME, Josephs KA (2011) Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 45:384–389. https://doi.org/10.1007/s12031-011-9589-0 · DOI · Paper page
  15. Ferrer I, López-González I, Carmona M, Arregui L, Dalfó E, Torrejón-Escribano B, Diehl R, Kovacs GG (2014) Glial and neuronal tau pathology in tauopathies: characterization of disease-specific phenotypes and tau pathology progression. J Neuropathol Exp Neurol 73:81–97. https://doi.org/10.1097/nen.0000000000000030 · DOI · Paper page
  16. Fukuda M et al (2009) Elevated levels of 4-hydroxynonenal-histidine Michael adduct in the hippocampi of patients with Alzheimer’s disease. Biomed Res 30:227–233 · DOI
  17. Ganfornina MD, Do Carmo S, Lora JM, Torres-Schumann S, Vogel M, Allhorn M, Gonzlez C, Bastiani MJ, Rassart E, Sanchez D (2008) Apolipoprotein D is involved in the mechanisms regulating protection from oxidative stress. Aging Cell 7:506–515. https://doi.org/10.1111/j.1474-9726.2008.00395.x · DOI
  18. Glockner F, Ohm TG (2003) Hippocampal apolipoprotein D level depends on Braak stage and APOE genotype. Neuroscience 122:103–110 · DOI · Paper page
  19. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA (1989) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 8:393–399 · DOI · Paper page
  20. Goedert M, Ghetti B, Spillantini MG (2012) Frontotemporal dementia: implications for understanding Alzheimer disease. Cold Spring Harb Perspect Med 2:a006254. https://doi.org/10.1101/cshperspect.a006254 · DOI
  21. He X, Jittiwat J, Kim JH, Jenner AM, Farooqui AA, Patel SC, Ong WY (2009) Apolipoprotein D modulates F2-isoprostane and 7-ketocholesterol formation and has a neuroprotective effect on organotypic hippocampal cultures after kainate-induced excitotoxic injury. Neurosci Lett 455:183–186. https://doi.org/10.1016/j.neulet.2009.03.038 · DOI
  22. Iguchi Y, Katsuno M, Takagi S, Ishigaki S, Niwa JI, Hasegawa M, Tanaka F, Sobue G (2012) Oxidative stress induced by glutathione depletion reproduces pathological modifications of TDP-43 linked to TDP-43 proteinopathies. Neurobiol Dis 45:862–870. https://doi.org/10.1016/j.nbd.2011.12.002 · DOI
  23. IR M, Manuela N (2016) Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. J Neurochem 138:54–70. https://doi.org/10.1111/jnc.13588 · DOI
  24. Irwin DJ, Cairns NJ, Grossman M, McMillan CT, Lee EB, van Deerlin VM, Lee VMY, Trojanowski JQ (2015) Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine. Acta Neuropathol 129:469–491. https://doi.org/10.1007/s00401-014-1380-1 · DOI
  25. Leyton C, Hodges J (2010) Frontotemporal dementias: recent advances and current controversies. Ann Indian Acad Neurol 13:74–80. https://doi.org/10.4103/0972-2327.74249 · DOI
  26. Li H, Ruberu K, Muñoz SS, Jenner AM, Spiro A, Zhao H, Rassart E, Sanchez D, Ganfornina MD, Karl T, Garner B (2015) Apolipoprotein D modulates amyloid pathology in APP/PS1 Alzheimer’s disease mice. Neurobiol Aging 36:1820–1833. https://doi.org/10.1016/j.neurobiolaging.2015.02.010 · DOI
  27. Mahadik SP, Khan MM, Evans DR, Parikh VV (2002) Elevated plasma level of apolipoprotein D in schizophrenia and its treatment and outcome. Schizophr Res 58:55–62 · DOI
  28. Martinez E, Navarro A, Ordonez C, Del Valle E, Tolivia J (2012) Amyloid-beta25-35 induces apolipoprotein D synthesis and growth arrest in HT22 hippocampal cells. J Alzheimers Dis 30:233–244. https://doi.org/10.3233/jad-2012-112102 · DOI
  29. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD (2005) F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 7:269–275. https://doi.org/10.1089/ars.2005.7.269 · DOI
  30. Muffat J, Walker DW, Benzer S (2008) Human ApoD, an apolipoprotein up-regulated in neurodegenerative diseases, extends lifespan and increases stress resistance in Drosophila. Proc Natl Acad Sci U S A 105:7088–7093. https://doi.org/10.1073/pnas.0800896105 · DOI
  31. Murphy KE, Cottle L, Gysbers AM, Cooper AA, Halliday GM (2013) ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun 1:11. https://doi.org/10.1186/2051-5960-1-11 · DOI
  32. Nishimura T, Ikeda K, Akiyama H, Arai T, Kondo H, Okochi M, Furiya Y, Mori H, Oda T, Kato M, Iseki E (1997) Glial tau-positive structures lack the sequence encoded by exon 3 of the tau protein gene. Neurosci Lett 224:169–172. https://doi.org/10.1016/s0304-3940(97)00161-4 · DOI
  33. Ordonez C, Navarro A, Perez C, Astudillo A, Martinez E, Tolivia J (2006) Apolipoprotein D expression in substantia nigra of Parkinson disease. Histol Histopathol 21:361–366. https://doi.org/10.14670/hh-21.361 · DOI
  34. Paola D, Domenicotti C, Nitti M, Vitali A, Borghi R, Cottalasso D, Zaccheo D, Odetti P, Strocchi P, Marinari UM, Tabaton M, Pronzato MA (2000) Oxidative stress induces increase in intracellular amyloid beta-protein production and selective activation of betaI and betaII PKCs in NT2 cells. Biochem Biophys Res Commun 268:642–646. https://doi.org/10.1006/bbrc.2000.2164 · DOI
  35. Pratico D, V MYL, Trojanowski JQ, Rokach J, Fitzgerald GA (1998) Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 12:1777–1783 · DOI · Paper page
  36. Rassart E, Bedirian A, Do Carmo S, Guinard O, Sirois J, Terrisse L, Milne R (2000) Apolipoprotein D. Biochim Biophys Acta 1482:185–198. https://doi.org/10.1016/S0167-4838(00)00162-X · DOI · Paper page
  37. Sanchez D, Bajo-Grañeras R, Del Caño-Espinel M, Garcia-Centeno R, Garcia-Mateo N, Pascua-Maestro R, Ganfornina MD (2015) Aging without apolipoprotein D: molecular and cellular modifications in the hippocampus and cortex. Exp Gerontol 67:19–47. https://doi.org/10.1016/j.exger.2015.04.003 · DOI
  38. Schweitzer K, Decker E, Zhu L, Miller RE, Mirra SS, Spina S, Ghetti B, Wang M, Murrell J (2006) Aberrantly regulated proteins in frontotemporal dementia. Biochem Biophys Res Commun 348:465–472. https://doi.org/10.1016/j.bbrc.2006.07.113 · DOI
  39. Suresh S, Yan Z, Patel RC, Patel YC, Patel SC (1998) Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D. J Neurochem 70:242–251 · DOI
  40. Tamagno E, Guglielmotto M, Aragno M, Borghi R, Autelli R, Giliberto L, Muraca G, Danni O, Zhu X, Smith MA, Perry G, Jo DG, Mattson MP, Tabaton M (2008) Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 104:683–695. https://doi.org/10.1111/j.1471-4159.2007.05072.x · DOI
  41. Tan RH, Shepherd CE, Kril JJ, McCann H, McGeachie A, McGinley C, Affleck A, Halliday GM (2013b) Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun 1:33. https://doi.org/10.1186/2051-5960-1-33 · DOI
  42. Tan RH, Kril JJ, Fatima M, McGeachie A, McCann H, Shepherd C, Forrest SL, Affleck A, Kwok JBJ, Hodges JR, Kiernan MC, Halliday GM (2015) TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. Brain 138:3110–3122. https://doi.org/10.1093/brain/awv220 · DOI
  43. Terrisse L et al (1998) Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer’s patients. J Neurochem 71:1643–1650 · DOI
  44. Thomas EA, Dean B, Pavey G, Sutcliffe JG (2001) Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders. Proc Natl Acad Sci U S A 98:4066–4071. https://doi.org/10.1073/pnas.071056198 · DOI
  45. Thomas EA, George RC, Sutcliffe JG (2003) Apolipoprotein D modulates arachidonic acid signaling in cultured cells: implications for psychiatric disorders. Prostaglandins Leukot Essent Fat Acids 69:421–427 · DOI
  46. Tong Y, Zhou W, Fung V, Christensen MA, Qing H, Sun X, Song W (2005) Oxidative stress potentiates BACE1 gene expression and Abeta generation. J Neural Transm (Vienna 1996) 112:455–469. https://doi.org/10.1007/s00702-004-0255-3 · DOI
  47. Tsuiji H, Inoue I, Takeuchi M, Furuya A, Yamakage Y, Watanabe S, Koike M, Hattori M, Yamanaka K (2017) TDP-43 accelerates age-dependent degeneration of interneurons. Sci Rep 7:14972. https://doi.org/10.1038/s41598-017-14966-w · DOI
  48. Tsukamoto K, Mani DR, Shi J, Zhang S, Haagensen DE, Otsuka F, Guan J, Smith JD, Weng W, Liao R, Kolodgie FD, Virmani R, Krieger M (2013) Identification of apolipoprotein D as a cardioprotective gene using a mouse model of lethal atherosclerotic coronary artery disease. Proc Natl Acad Sci U S A 110:17023–17028. https://doi.org/10.1073/pnas.1315986110 · DOI
  49. Williams TI, Lynn BC, Markesbery WR, Lovell MA (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer’s disease. Neurobiol Aging 27:1094–1099. https://doi.org/10.1016/j.neurobiolaging.2005.06.004 · DOI
  50. Yoshida M (2006) Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 26:457–470. https://doi.org/10.1111/j.1440-1789.2006.00743.x · DOI

Cited by

Sorted by citations

See all 40

Metadata

Authors
Bhatia, S., Kim, W. S., Shepherd, C. E., & Halliday, G. M.
Venue
Journal of Molecular Neuroscience
Publisher
Springer Science and Business Media LLC
Published
2018-11-22
Volume
67
Issue
1
Pages
125-132
ISSN
  • 0895-8696
  • 1559-1166
DOI
10.1007/s12031-018-1217-9
PMC
PMC6344390
Cited by
40
References
5
Language
en
Licence
creativecommons.org/licenses/by/4.0 (tdm)
Funders
National Health and Medical Research Council (APP1108882)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apolipoprotein D Upregulation in Alzheimer’s Disease but Not Frontotemporal Dementia. https://app.cochat.ai/papers/10.1007/s12031-018-1217-9
The paper
Bhatia, S., Kim, W. S., Shepherd, C. E., & Halliday, G. M. (2019). Apolipoprotein D Upregulation in Alzheimer’s Disease but Not Frontotemporal Dementia. Journal of Molecular Neuroscience. https://doi.org/10.1007/s12031-018-1217-9